Sernova and Seraxis Close $11.2M Financing to Fund BetaNova Merger

Key Facts

1Sernova and Seraxis closed a $11.2 million convertible note financing to fund their merger and form BetaNova Biotherapeutics.

Sernova and Seraxis closed a $11.2 million convertible note financing to fund their merger and form BetaNova Biotherapeutics. Reuters reported that the funding is intended to facilitate the merger and advance cell therapy for Type 1 diabetes into Phase 1/2 clinical trials.

SEOVF closed at $0.0776 on October 2, 2026, marking the high point of a session that saw a low of $0.0733. The successful financing round provides direct capital for the previously announced merger milestones as the companies work toward finalized integration.